Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised IDEAYA Biosciences, while Davis Polk advised the underwriters in the offering. IDEAYA Biosciences, Inc. executed its public offering of 5,333,333 shares of common...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
You must be a Standard 1 Year member to access this content.
